JP2024501471A5 - - Google Patents
Info
- Publication number
- JP2024501471A5 JP2024501471A5 JP2023535799A JP2023535799A JP2024501471A5 JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5 JP 2023535799 A JP2023535799 A JP 2023535799A JP 2023535799 A JP2023535799 A JP 2023535799A JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125371P | 2020-12-14 | 2020-12-14 | |
| US63/125,371 | 2020-12-14 | ||
| PCT/US2021/063130 WO2022132652A1 (en) | 2020-12-14 | 2021-12-13 | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501471A JP2024501471A (ja) | 2024-01-12 |
| JP2024501471A5 true JP2024501471A5 (https=) | 2024-12-23 |
| JPWO2022132652A5 JPWO2022132652A5 (https=) | 2024-12-23 |
Family
ID=79288002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535799A Pending JP2024501471A (ja) | 2020-12-14 | 2021-12-13 | エストロゲン受容体分解剤としてのテトラヒドロナフタレン誘導体を用いる乳がんを治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220193072A1 (https=) |
| EP (1) | EP4259137A1 (https=) |
| JP (1) | JP2024501471A (https=) |
| KR (1) | KR20230121801A (https=) |
| CN (1) | CN116744925A (https=) |
| AU (1) | AU2021401580A1 (https=) |
| CA (1) | CA3202592A1 (https=) |
| IL (1) | IL303143A (https=) |
| MX (1) | MX2023007058A (https=) |
| TW (1) | TW202237117A (https=) |
| WO (1) | WO2022132652A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN115746058A (zh) * | 2021-09-03 | 2023-03-07 | 南京知和医药科技有限公司 | 一种多环化合物在制备抗肿瘤药物方面的用途 |
| KR20250047743A (ko) * | 2022-07-12 | 2025-04-04 | 리젠츠 오브 더 유니버시티 오브 미시간 | 에스트로겐 수용체 분해제로서의 테트라하이드로나프탈렌 유도체 |
| WO2024049926A1 (en) * | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
| WO2024196053A1 (ko) * | 2023-03-17 | 2024-09-26 | 재단법인 대구경북첨단의료산업진흥재단 | 에스트로겐-연관 수용체 감마 억제제 및 항암제의 병용요법용 조성물 |
| TW202440096A (zh) * | 2023-03-24 | 2024-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| CN121368483A (zh) * | 2023-06-02 | 2026-01-20 | 辉瑞公司 | 雌激素受体降解剂与cdk4抑制剂的组合 |
| EP4719399A1 (en) * | 2023-06-02 | 2026-04-08 | Arvinas Operations, Inc. | Combinations of estrogen receptor degraders and akt inhibitors |
| WO2025122502A1 (en) * | 2023-12-04 | 2025-06-12 | Foundation Medicine, Inc. | Methods for treating hr-positive her2-negative breast cancer |
| CN121646481A (zh) * | 2024-07-04 | 2026-03-10 | 海创药业股份有限公司 | 一种雌激素受体降解剂和akt抑制剂联合用药物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2017507964A (ja) * | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
| JP7019422B2 (ja) * | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ，インコーポレイテッド | 癌を治療するための方法 |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| CA3095912A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN113164779A (zh) * | 2018-12-06 | 2021-07-23 | 雷迪厄斯制药公司 | 治疗cdk4/6抑制剂耐药性癌症的方法 |
| IL320609A (en) * | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
-
2021
- 2021-12-13 CN CN202180092119.4A patent/CN116744925A/zh active Pending
- 2021-12-13 MX MX2023007058A patent/MX2023007058A/es unknown
- 2021-12-13 WO PCT/US2021/063130 patent/WO2022132652A1/en not_active Ceased
- 2021-12-13 IL IL303143A patent/IL303143A/en unknown
- 2021-12-13 AU AU2021401580A patent/AU2021401580A1/en active Pending
- 2021-12-13 CA CA3202592A patent/CA3202592A1/en active Pending
- 2021-12-13 KR KR1020237023551A patent/KR20230121801A/ko active Pending
- 2021-12-13 EP EP21840327.7A patent/EP4259137A1/en active Pending
- 2021-12-13 US US17/548,842 patent/US20220193072A1/en active Pending
- 2021-12-13 TW TW110146570A patent/TW202237117A/zh unknown
- 2021-12-13 JP JP2023535799A patent/JP2024501471A/ja active Pending